EGFR p.L858R
About
Gene context: EGFR
Biomarker Type: Somatic Variant
Present: True
Chromosome: 7
Start Position: 55259515
End Position: 55259515
Reference Allele: T
Alternate Allele: G
Cdna Change: c.2573T>G
Protein Change: p.L858R
Variant Annotation: Missense
Exon: 21
Rsid: rs121434568
Hgvsg: 7:g.55259515T>G
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Dacomitinib | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Gefitinib | |
| EMA (2) FDA (3) | EGFR p.L858R | Non-Small Cell Lung Cancer | Osimertinib | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| EMA (3) FDA (2) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| EMA (1) FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| EMA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib | |
| EMA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib | |
| EMA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Datopotamab deruxtecan |